LENZ Therapeutics
LENZ
105 hedge funds and large institutions have $542M invested in LENZ Therapeutics in 2025 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 31 increasing their positions, 27 reducing their positions, and 12 closing their positions.
92% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 12
15% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 27
12% more funds holding
Funds holding: 94 → 105 (+11)
4.28% more ownership
Funds ownership: 72.23% → 76.52% (+4.3%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
5% less capital invested
Capital invested by funds: $573M → $542M (-$31.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
+$18.3M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$14.3M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$13.2M |
| 4 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$3.06M |
| 5 |
SM
Scoggin Management
New York
|
+$2.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$12.7M |
| 2 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$11.3M |
| 3 |
State Street
Boston,
Massachusetts
|
-$5.1M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
-$4.32M |
| 5 |
TD Asset Management
Toronto,
Ontario, Canada
|
-$1.68M |
LENZ Hedge Fund Activity: Q1 2025 in Review
105 of the 7,471 institutional investors tracked by Wall St. Rank reported a position in LENZ Therapeutics (LENZ) for Q1 2025, worth a combined $542M — down 5.5% from $573M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new LENZ positions and 12 closed out — a net gain of 11 holders — while 31 added to existing stakes and 27 trimmed.
The largest buyer was Paradigm Biocapital Advisors, adding an estimated $18.3M. The largest seller was T. Rowe Price Associates, cutting an estimated $12.7M.
- 105 institutional investors held LENZ Therapeutics (LENZ) as of Q1 2025, up from 94 in Q4 2024.
- Funds reported $542M of LENZ Therapeutics stock for Q1 2025, down 5.5% quarter-over-quarter.
- 23 funds opened new LENZ Therapeutics positions in Q1 2025 and 12 closed out, a net change of +11 holders.
- The largest LENZ Therapeutics buyer in Q1 2025 was Paradigm Biocapital Advisors, an estimated $18.3M added.
- The largest LENZ Therapeutics seller in Q1 2025 was T. Rowe Price Associates, an estimated $12.7M sold.
Based on aggregated 13F filings for Q1 2025.